<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01625091</url>
  </required_header>
  <id_info>
    <org_study_id>86-2012-N</org_study_id>
    <secondary_id>U01AA020797-01</secondary_id>
    <nct_id>NCT01625091</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Reduce Drinking in Women With HIV</brief_title>
  <acronym>WHATIF</acronym>
  <official_title>Pharmacotherapy for Alcohol Consumption in HIV Infected Women: Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Florida International University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rush University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate whether an intervention that involves the&#xD;
      medication naltrexone, will reduce drinking and improve health outcomes in women with HIV&#xD;
      infection and hazardous drinking. Our central hypotheses are that, compared to women who&#xD;
      receive placebo (sugar pill containing no medicine), women who receive naltrexone will have&#xD;
      decreased rates of hazardous drinking, improved HIV medication adherence, less rapid disease&#xD;
      progression, and reduced sexual risk behavior. The study design will involve 240 HIV-infected&#xD;
      women with hazardous drinking, who will be recruited from HIV clinics, neighborhoods and&#xD;
      referrals in Miami, Florida.&#xD;
&#xD;
      Eligible women will receive either a daily pill containing naltrexone (50mg) or an&#xD;
      identical-appearing placebo for four months. All participants will receive encouragement and&#xD;
      feedback related to their drinking regardless of medication assignment. The study&#xD;
      participants will be assessed at two, four and seven months after enrollment. The proposed&#xD;
      work is innovative because pharmacologic treatment for alcohol has not been evaluated in&#xD;
      HIV-infected women. If our hypotheses are confirmed, the study findings would transform the&#xD;
      approach to hazardous drinking within clinics serving HIV-infected women.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to evaluate the acceptability and effectiveness of a&#xD;
      treatment program for hazardous drinking, delivered within HIV-clinic outpatient settings,&#xD;
      that involves oral naltrexone. The central hypothesis is that women participating in the&#xD;
      treatment program will have decreased rates of hazardous drinking and improved clinical and&#xD;
      behavioral health outcomes that are associated with hazardous drinking. The investigators&#xD;
      have formulated this hypotheses based on the existing literature, the preliminary data and&#xD;
      the clinical experience. The investigators theorize that women who receive an alcohol&#xD;
      treatment intervention will be less likely to have &quot;at risk&quot; drinking behavior 6-months after&#xD;
      enrollment, compared to women who received similar assessments but no formal treatment&#xD;
      intervention. The investigators hypothesize that 4-months after enrollment, women who receive&#xD;
      an alcohol treatment intervention will have improved adherence to HIV antiretroviral therapy,&#xD;
      improved CD4 cell counts, reduced HIV viral load, and reduced risky sexual behavior, compared&#xD;
      to women who receive similar assessments but no formal intervention.&#xD;
&#xD;
      The investigators will recruit 240 women from one site in Miami, Florida. Of those 240 women&#xD;
      120 will receive naltrexone and the others will receive placebo. Study participants will take&#xD;
      the medication for 4 months but the investigators will follow them for 7 months. At baseline,&#xD;
      2 months, 4 months and 7 months, the investigators will administer study questionnaires and&#xD;
      assess their liver enzymes, CD4 count and viral load. The investigators will also follow them&#xD;
      up at months 1 and 3 to reinforce the medication intake and to assess for any possible side&#xD;
      effects.&#xD;
&#xD;
      New treatment options are available, but their impact on hazardous drinking has not yet been&#xD;
      evaluated among HIV-infected women, many of whom are poor, minorities, or who have associated&#xD;
      mental health or substance abuse problems. Delivery of therapeutic interventions must be&#xD;
      improved in order to reduce hazardous drinking in women with HIV/AIDS. The proposed research&#xD;
      is significant because the therapy will be offered within HIV clinic settings and will&#xD;
      potentially improve the health of a population that is significantly undertreated. In&#xD;
      addition to determining the effectiveness of an alcohol treatment intervention, the&#xD;
      investigators will also identify key barriers and facilitators associated with adherence to&#xD;
      pharmacologic treatment for alcohol in women with hazardous drinking. The findings will&#xD;
      directly affect the type and quality of care for hazardous drinking in this subset of&#xD;
      HIV-infected individuals and will inform both primary and secondary prevention efforts.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2012</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Quit Hazardous Drinking</measure>
    <time_frame>Month 4</time_frame>
    <description>The primary statistical outcome for the trial is alcohol consumption at month 4 when the drug is stopped. This main outcome is a categorical variable of either quit hazardous drinking (defined as ≤7 drinks per week and &lt;4 drinks on any single day in the past 30 days), or did not quit (drinking exceeds the hazardous amount) .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Binge Drinking Days</measure>
    <time_frame>Month 4</time_frame>
    <description>In the past 30 days, total number of days with binge drinking which was defined as consuming ≥4 drinks on a single day (measured by Timeline Follow Back).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drinking Problems (SIP-2R Score)</measure>
    <time_frame>4 months</time_frame>
    <description>The Short Inventory of Problems (SIP-2R) seeks to measure the consequences of drinking in participants through questions related to guilt, reliability etc. The SIP-2R has 15 items asking how often the event happened during the past 3 months. Each item has a score from 0-3 (0=Never, 1=once or a few times, 2=once or twice a week, 3=daily or almost daily). The 15 questions from the SIP-2R are summed to create a total range of scores from 0-45.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Craving for Alcohol</measure>
    <time_frame>4 months</time_frame>
    <description>Self-reported scale of alcohol craving ranging from 0 (no craving) to 10 (strongest craving)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">194</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>naltrexone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The investigators will administer Naltrexone to women with hazardous drinking and assess the study outcomes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The investigators will administer an inert placebo that looks similar to Naltrexone, to women with hazardous drinking and assess the study outcomes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone</intervention_name>
    <description>The study involves taking the drug naltrexone for up to 4 months. This will be given in a single pill each day for 4 months.</description>
    <arm_group_label>naltrexone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo is an inert pill that looks the same as naltrexone. The placebo will be taken once each day for up to 4 months.</description>
    <arm_group_label>placebo pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: (must meet all of following):&#xD;
&#xD;
          -  Hazardous drinking, on average, during the preceding 4 weeks. Defined as binge&#xD;
             drinking (4 or more drinks per occasion at least twice monthly) and/or high total&#xD;
             weekly consumption (&gt;7 drinks per week).&#xD;
&#xD;
          -  Age 18 or over&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  HIV infection (documented by medical record blood test result or testing done for this&#xD;
             study)&#xD;
&#xD;
          -  Able to understand and comply with study procedures and to provide written consent.&#xD;
&#xD;
        Exclusion criteria: (cannot have any of the following):&#xD;
&#xD;
          -  Contraindications to treatment with naltrexone&#xD;
&#xD;
          -  Current physiologic opiate dependence&#xD;
&#xD;
          -  Current daily prescription opioid medications&#xD;
&#xD;
          -  Positive urine drug test for opioids&#xD;
&#xD;
          -  Allergic to naltrexone&#xD;
&#xD;
          -  Significantly abnormal baseline liver enzymes (AST or ALT &gt;=5 times upper normal),&#xD;
             evidence of acute hepatitis, or receiving hemodialysis for renal failure&#xD;
&#xD;
          -  Currently pregnant&#xD;
&#xD;
          -  Currently taking an alcohol treatment medication (disulfiram, topiramate, naltrexone,&#xD;
             acamprosate).&#xD;
&#xD;
          -  Currently unable to provide mailing address or reliable contact information, or has&#xD;
             plans to move from area within next 7 months&#xD;
&#xD;
          -  Unable to communicate in English or Spanish&#xD;
&#xD;
          -  Research coordinator assessment that participant cannot comprehend the study or&#xD;
             consent procedures (e.g. participant appears to be intoxicated, answers questions in a&#xD;
             non-sensible manner)&#xD;
&#xD;
          -  Has current prognosis of less than one year to live (e.g. in Hospice, has metastatic&#xD;
             cancer)&#xD;
&#xD;
          -  Currently taking antiviral treatment for hepatitis C infection (interferon or&#xD;
             ribavirin)&#xD;
&#xD;
          -  Has other unique health condition, not specifically listed, that should exclude the&#xD;
             participant after discussion with Dr. Cook, Dr. Espinoza, and perhaps also the&#xD;
             participant's primary HIV physician (for example an unexpected abnormal laboratory&#xD;
             result turns up on the baseline screening metabolic panel).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert L Cook, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida International University</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 12, 2012</study_first_submitted>
  <study_first_submitted_qc>June 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2012</study_first_posted>
  <results_first_submitted>July 6, 2017</results_first_submitted>
  <results_first_submitted_qc>July 6, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 2, 2017</results_first_posted>
  <last_update_submitted>June 12, 2018</last_update_submitted>
  <last_update_submitted_qc>June 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>women</keyword>
  <keyword>drinking</keyword>
  <keyword>Naltrexone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Naltrexone</title>
          <description>The participants took the drug naltrexone one single pill (50mg) each day for up to 4 months and then received final assessment at 7-months.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>The participants took an inert placebo one single pill each day for up to 4-months and then received final assessment at 7-months. Placebo is an inert pill that looks the same as naltrexone.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="98"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>2 Months</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="93"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>4 Months</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="87"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="87"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study termination</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Post-intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="87"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>7 Months</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study termination</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Naltrexone</title>
          <description>The participants took the drug naltrexone one single pill (50mg) each day for up to 4 months and then received final assessment at 7-months.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>The participants took an inert placebo one single pill each day for up to 4-months and then received final assessment at 7-months. Placebo is an inert pill that looks the same as naltrexone.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="96"/>
            <count group_id="B2" value="98"/>
            <count group_id="B3" value="194"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.7" spread="8.5"/>
                    <measurement group_id="B2" value="48.9" spread="8.9"/>
                    <measurement group_id="B3" value="48.3" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Age group</title>
              <category_list>
                <category>
                  <title>18-39</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>40-49</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>50-59</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥60</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="194"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race/Ethnicity</title>
              <category_list>
                <category>
                  <title>Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic, White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic, Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="161"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic, Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Quit Hazardous Drinking</title>
        <description>The primary statistical outcome for the trial is alcohol consumption at month 4 when the drug is stopped. This main outcome is a categorical variable of either quit hazardous drinking (defined as ≤7 drinks per week and &lt;4 drinks on any single day in the past 30 days), or did not quit (drinking exceeds the hazardous amount) .</description>
        <time_frame>Month 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone</title>
            <description>The participants took the drug naltrexone one single pill (50mg) each day for up to 4 months and then received final assessment at 7-months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>The participants took an inert placebo one single pill each day for up to 4-months and then received final assessment at 7-months. Placebo is an inert pill that looks the same as naltrexone.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Quit Hazardous Drinking</title>
          <description>The primary statistical outcome for the trial is alcohol consumption at month 4 when the drug is stopped. This main outcome is a categorical variable of either quit hazardous drinking (defined as ≤7 drinks per week and &lt;4 drinks on any single day in the past 30 days), or did not quit (drinking exceeds the hazardous amount) .</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.36</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Binge Drinking Days</title>
        <description>In the past 30 days, total number of days with binge drinking which was defined as consuming ≥4 drinks on a single day (measured by Timeline Follow Back).</description>
        <time_frame>Month 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone</title>
            <description>The participants took the drug naltrexone one single pill (50mg) each day for up to 4 months and then received final assessment at 7-months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>The participants took an inert placebo one single pill each day for up to 4-months and then received final assessment at 7-months. Placebo is an inert pill that looks the same as naltrexone.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Binge Drinking Days</title>
          <description>In the past 30 days, total number of days with binge drinking which was defined as consuming ≥4 drinks on a single day (measured by Timeline Follow Back).</description>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.36</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Drinking Problems (SIP-2R Score)</title>
        <description>The Short Inventory of Problems (SIP-2R) seeks to measure the consequences of drinking in participants through questions related to guilt, reliability etc. The SIP-2R has 15 items asking how often the event happened during the past 3 months. Each item has a score from 0-3 (0=Never, 1=once or a few times, 2=once or twice a week, 3=daily or almost daily). The 15 questions from the SIP-2R are summed to create a total range of scores from 0-45.</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone</title>
            <description>The participants took the drug naltrexone one single pill (50mg) each day for up to 4 months and then received final assessment at 7-months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>The participants took an inert placebo one single pill each day for up to 4-months and then received final assessment at 7-months. Placebo is an inert pill that looks the same as naltrexone.</description>
          </group>
        </group_list>
        <measure>
          <title>Drinking Problems (SIP-2R Score)</title>
          <description>The Short Inventory of Problems (SIP-2R) seeks to measure the consequences of drinking in participants through questions related to guilt, reliability etc. The SIP-2R has 15 items asking how often the event happened during the past 3 months. Each item has a score from 0-3 (0=Never, 1=once or a few times, 2=once or twice a week, 3=daily or almost daily). The 15 questions from the SIP-2R are summed to create a total range of scores from 0-45.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="9.9"/>
                    <measurement group_id="O2" value="6.7" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.70</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Craving for Alcohol</title>
        <description>Self-reported scale of alcohol craving ranging from 0 (no craving) to 10 (strongest craving)</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone</title>
            <description>The participants took the drug naltrexone one single pill (50mg) each day for up to 4 months and then received final assessment at 7-months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>The participants took an inert placebo one single pill each day for up to 4-months and then received final assessment at 7-months. Placebo is an inert pill that looks the same as naltrexone.</description>
          </group>
        </group_list>
        <measure>
          <title>Craving for Alcohol</title>
          <description>Self-reported scale of alcohol craving ranging from 0 (no craving) to 10 (strongest craving)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="3.4"/>
                    <measurement group_id="O2" value="3.2" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.98</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Naltrexone</title>
          <description>The participants took the drug naltrexone one single pill (50mg) each day for up to 4 months and then received final assessment at 7-months.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>The participants took an inert placebo one single pill each day for up to 4-months and then received final assessment at 7-months. Placebo is an inert pill that looks the same as naltrexone.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Inpatient hospitalization</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="96"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Sleepiness</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Nervousness/Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Itchiness</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Robert Cook</name_or_title>
      <organization>Unversity of Florida</organization>
      <phone>352-273-5869</phone>
      <email>cookrl@ufl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

